The curative effect of ALSS on 1-month mortality in AoCLF patients after 72 to 120 hours

International Journal of Artificial Organs

Volumn 30, Issue 10, 2007, Pages 906-914

  Chen, Y S ^a   Wu, Z W ^a   He, J Q ^a   Yu, J ^a   Yang, S G ^a   Zhang, Y M ^a   Du, W B ^a   Cao, H C ^a   Li, Lan Juan ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Artificial liver support system; Mortality; Organ allocation priorities; Risk factor

Indexed keywords

ARTIFICIAL ORGANS; DIAGNOSIS; NEURODEGENERATIVE DISEASES; VIRUSES;

ACUTE-ON-CHRONIC LIVER FAILURE; ARTIFICIAL LIVER SUPPORT SYSTEMS; CURATIVE EFFECTS; HEPATITIS B VIRUS; INTERNATIONAL NORMALIZED RATIOS; MORTALITY; MORTALITY RATE; ORGAN ALLOCATION PRIORITY; RISK FACTORS; SELF REGENERATION;

REGRESSION ANALYSIS;

ACETYLCHOLINESTERASE; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BICARBONATE; BILE ACID; BILIRUBIN; CREATININE; GLOBULIN; POTASSIUM; UREA;

ACCURACY; ADULT; ARTICLE; BLEEDING; CELL REGENERATION; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; DEATH; DETERIORATION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEMOFILTRATION; HEMOPERFUSION; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERKALEMIA; HYPOTENSION; INJECTION SITE INFECTION; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIVER CELL; LIVER FAILURE; LIVER SUPPORT; LIVER TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PLASMAPHERESIS; PREDICTION; PROGNOSIS; RASH; RESOURCE ALLOCATION; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

EID: 38149091512     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703001008     Document Type: Article

References (25)

1. Shakil AO, Kramer D, Mazariegos GV, Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000; 6: 163-9.
2. Mas A, Rodes J. Fulminant hepatic failure. Lancet 1997; 349: 1081-5.
3. Charpman RW, Forman D, Peto R, Smallwood R. Liver transplantation for acute hepatic failure? Lancet 1990; 335: 32-5.
4. Nyberg SL, Peshwa MV, Payne WD, Hu WS, Cerra FB. Evolution of the bioartificial liver: the need for randomized clinical trials. Am J Surg 1993; 166: 512-21.
5. Du WB, Li LJ, Huang JR, Yang Q, Liu XL, Li J, Chen YM, Cao HC, Xu W, Fu SZ, and Chen YG. Effects of artificial liver support system on patients with acute or chronic liver failure. Transplant Proc 2005; 37: 4359-64.
6. Li LJ, Yang Q, Huang JR, Xu XW, Chen YM, Fu SZ. Effect of artificial liver support system on patients with severe viral hepatitis: a study of four hundred cases. World J Gastroenterol 2004; 10: 2984-8.
7. Wiles CE. Critical care apheresis: hepatic failure. Ther Apher 1999; 3: 31-3.
8. Iwai H, Nagaki M, Naito T, Ishiki Y, Murakami N, Sugihara J, Muto Y, Moriwaki H. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med 1998; 26: 873-6.
9. Silk DB, Trewby PN, Chase RA, Mellon PJ, Hanid MA, Davies M, Langley PG, Wheeler PG, Williams R. Treatment of fulminant hepatic failure by polyacrylonitrile-membrane of haemodialysis. Lancet 1977; 2: 1-3.
10. Redeker AG, Yamihiro HS. Controlled trial of exchange transfusion therapy in fulminant hepatitis. Lancet 1993; 1: 2-3.
11. O'Grady JG, Gimson AE, O'Brein CJ, Pucknell A, Hughes RD, Williams R. Controlled trails of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1998; 94 (5 Pt 1): 1186-92.
12. Kondrup J, Almdal T, Vilstrup H, Tygstrup N. High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs 1992; 15: 669.
13. Shin K, Nagai Y, Hirano C, Kataoka N, Ono I, Yamamura E, Moriyama C, Horigome Y, Ehara T, Kamoda T. Survival rate in children with fulminant hepatitis improved by a combination of twice daily plasmapheresis and intensive conservative therapy. J Pediatr Gastroenterol Nutr 1989; 9: 163-6.
14. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure - a systematic review. JAMA 2003; 289: 217-22.
15. Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol 1999; 5: 301-4.
16. Qian YB, Cheng GH, Huang JF. Multivariate regression analysis on early mortality after orthotopic liver transplantation. World J Gastroenterol 2002; 8: 128-30.
17. Arun Kundra, Anil Jain, Alok Banga, Girish Bajaj, Premasish Kar. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem 2005; 38: 696-9.
18. Chan PC, Chen HL, Kong MS, Huang FC, Lee HC, Lin CC, Liu CC, Lee IH, Wu TC, Wu SF, Ni YH, Hsu HY, Chang MH. Factors affecting the mortality of pediatric fulminant hepatic failure in relation to hepatitis B virus infection. J Gastroenterol Hepatol 2005; 20: 1223-7.
19. Leblanc M, Kellum, JA. Gibney RT, Lieberthal W, Tumlin J, Mehta R. Risk factors for acute renal failure: inherent and modifiable risks. Curr Opin Crit Care 2005; 11: 533-6.
20. Gines A, Escorell A, Gines P, Salo J, Jimenez W, Inqlada, L, Navasa M, Claria J, Rimola A, Arroyo V, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
21. Takahashi Y, Kumada H, Shimizu M, Tanikawa K, Kumashiro R, Omata M, Ehata T, Tsuji T, Ukida M, Yasunaga M, et al. A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation. Hepatology 1994; 19: 1065-71.
22. Bismuth H, Samuel D, Castaing D, Williams R, Pereira SP. Liver transplantation in Europe for patients with acute liver failure. Semin Liver Dis 1996; 16: 415-25.
23. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-45.
24. Bloomer JR, Waldmann TA, Klatskin G. Serum afetoprotein in patients with massive hepatic necrosis. Gastroenterology 1997; 72: 479-82.
25. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897-903.